2003NCCN非小细胞肺癌诊疗指南(英文)

指南 肺癌

Clinical Practice Guidelines in Oncology– v.1.2003

Non-Small Cell Lung CancerVersion 1.2003

Continue

指南 肺癌

NCCN

Practice Guidelines in Oncology– v.1.2003

Non-Small Cell Lung Cancer

Guidelines Index NSCL Table of Contents Staging, MS, References

NCCN Non-Small Cell Lung Cancer Panel Members* David S. Ettinger, MD/Chair The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Athanassios Argiris, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Gerold Bepler, MD, PhD H. Lee Moffitt Cancer Center& Research Institute at the University of South Florida James D. Cox, MD University of Texas M. D. Anderson Cancer Center Thomas A. D’Amico, MD Duke Comprehensive Cancer Center Todd L. Demmy, MD Roswell Park Cancer Institute Fred Grannis, MD City of Hope Cancer Center Mark Iannettoni, MD University of Michigan Comprehensive Cancer Center Thierry Jahan, MD UCSF Comprehensive Cancer Center Mohammed Jahanzeb, MD St. Jude Children’s Research Hospital/University of Tennessee Cancer Institute Anne Kessinger, MD UNMC Eppley Cancer Center at the University of Nebraska Medical Center Ritsuko Komaki, MD University of Texas M. D. Anderson Cancer Center Mark G. Kris, MD Memorial Sloan-Kettering Cancer Center Corey J. Langer, MD Fox Chase Cancer Center Gregory A. Masters, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Gregory A. Otterson, MD Arthur G. James Cancer Hospital& Richard J. Solove Research Institute at The Ohio State University Stephen H. Petersdorf, MD Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance Francisco Robert, MD University of Alabama at Birmingham Comprehensive Cancer Center David J. Sugarbaker, MD Brigham& Women’s Hospital Henry Wagner, MD H. Lee Moffitt Cancer Center& Research Institute at the University of South Florida Gordon Watson, MD Huntsman Cancer Institute at the University of Utah Douglas E. Wood, MD Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

* Writing Committee member

Continue

Version 1.2003, 09/01/03 2003 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN.

指南 肺癌

NCCN

Practice Guidelines in Oncology– v.1.2003

Non-Small Cell Lung Cancer

Guidelines Index NSCL Table of Contents Staging, MS, References

Table of ContentsNCCN Non-Small Cell Lung Cancer Panel Members Lung Cancer Prevention and Screening (PREV-1) Initial Evaluation and Clinical Stages (NSCL-1) Evaluation and Treatment: ! Stage I (T1-2, N0) and Stage II (T1-2, N1) (NSCL-2) ! Stage IIB (T3, N0) and Stage IIIA (T3, N1) (NSCL-3) ! Stage IIIA (T1-3, N2) and Stage IIIB (T4, N0-1) (NSCL-6) ! Stage IIIB (T1-3, N3), Stage IIIB (T4, N2-3) and Stage IIIB (T4: pleural effusion) (NSCL-9) ! Stage IV (M1: solitary site and disseminated) (NSCL-10) Surveillance (NSCL-11) Therapy for Recurrence and Metastasis (NSCL-11) Occult (TX, N0,

M0), Evaluation and Treatment (NSCL-14) Second Lung Primary, Evaluation and Treatment (NSCL-14) Principles of Surgical Resection (NSCL-A) Chemotherapy Agents for Non-Small Cell Lung Cancer (NSCL-B) Guidelines Index Print the Non-Small Cell Lung Cancer GuidelineFor help using these documents, please click here

Staging Manuscript References

This manuscript is being updated to correspond with the newly updated algorithm.

Clinical Trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. To find clinical trials online at NCCN member institutions, click here: http://doc.guandang.net/clinical_trials/physician.htmlNCCN Categories of Consensus:

All recommendations are Category 2A unless otherwise specified. See NCCN Categories of Consensus

These guidelines are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no representations nor warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. These guidelines are copyrighted by National Comprehensive Cancer Network. All rights reserved. These guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. 2003.Version 1.2003, 09/01/03 2003 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN.

指南 肺癌

NCCN

Practice Guidelines in Oncology– v.1.2003

Non-Small Cell Lung Cancer

Guidelines Index NSCL Table of Contents Staging, MS, References

LUNG CANCER PREVENTION AND SCREENING

Lung Cancer is a unique disease in that the etiologic agent is an industry. More than 90% of cases are caused by cigarette smoking or involuntary smoking. Reduction of lung cancer mortality will require effective public health policies to prevent initiation of smoking, Federal Drug Administration (FDA) oversight of tobacco products and other tobacco control measures. Further complicating this problem, the delivery system of carcinogens also contains the highly addictive substance, nicotine. Reduction of lung cancer mortality will require widespread implementation of Agency for Healthcare Research and Quality (AHCPR) Guidelines to identify, counsel and treat patients with nicotine habituation. In recognition of the fact that …… 此处隐藏：24486字，全部文档内容请下载后查看。喜欢就下载吧 ……